Catalyst Pharmaceuticals, Inc. (CPRX) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Earnings Reports
-
Catalyst Pharmaceuticals (CPRX) Q4 2025: Agamri Surges 154%, Expanding Rare Disease Franchise
February 26, 2026
-
Catalyst Pharmaceuticals (CPRX) Q3 2025: Agamri Surges 115%, Expanding Rare Disease Growth Engine
November 06, 2025
-
Catalyst (CPRX) Q2 2025: Agamree Revenue Jumps 213% as Oncology Push Accelerates
August 07, 2025
-
Catalyst Pharmaceuticals (CPRX) Q1 2025: Net Income Jumps 144% as Rare Disease Portfolio Drives Durable Growth
July 06, 2025